As a result, the majority of genomic alterations are distinct between squamous (e.g., cyclin dependent kinase inhibitor 2A (CDKN2A) and tumor protein p53 (TP53)) and adenocarcinoma (e.g., KRAS proto‐oncogene (KRAS) and epidermal growth factor receptor (EGFR)) NSCLC.7 The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.